semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Breast Cancer Clinical, mammographic, MR-tomographic and/or ultrasonographic verification of a suspicious breast lesion (BIRADS 4 and 5) Age > 18 years Written informed consent Histopathological verification of the lesions either by core biopsy or by surgical excision  Unstable or non-compliant patients Pregnant or lactating patients or patients with suspected pregnancy Known contraindication to the intravenous administration of US contrast agents Acute or chronic renal insufficiency Pre or post-transplant patients
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pancreatic Neoplasms a solid pancreatic lesion with diameter larger than 20mm, with or without a cystic component, with unknown histology age above 18 years old signed informed consent  a solid pancreatic mass with a diameter less than 20mm or with known histology a cystic pancreatic mass, without a solid component coagulation disorder (international normalized ratio above 1.5, activated partial thromboplastin time above 42 seconds, platelet count less than 60000/mmc) or impossibility to stop antiaggregants or anticoagulants according to the European Society of Digestive Endoscopy guidelines European Cooperative Oncology Group status 4 American Society of Anesthesiology score higher than 3 pregnant women age under 18 years old refusal or impossibility to sign informed consent
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 40.0-69.0,  Endometrial Cancer Postmenopausal Bleeding postmenopausal woman referrals for the symptom of PMB  dementia mental retardation
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Breast Cancer Female sex Age 35 years or older Any ethnicity Have an abnormality detected by Breast Self Exam (BSE), or Clinical Breast Exam (CBE), or have an abnormality detected by an imaging modality. Will undergo study imaging within four weeks from the date of diagnostic mammography, prior to breast biopsy (if needed). Able to provide informed consent Post-menopausal, surgically sterile, or effective birth control. For women of childbearing potential, negative pregnancy test or has signed pregnancy test waiver If required by standard of care, eGFR >45 within 48 hours to 6 weeks of CE-CBBCT exam  Pregnancy Lactation Unknown pregnancy status AND has refused pregnancy testing and has refused to sign a pregnancy test waiver Women who are unable or unwilling to understand or to provide informed consent Women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker. Women who are unable to tolerate study constraints. Women who have received radiation treatments to the thorax or breast area for malignant and nonmalignant conditions, such as (but not limited to): Treatment for enlarged thymus gland as an infant Irradiation for benign breast conditions, including breast inflammation after giving birth Treatment for Hodgkin's disease Women who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram. Women who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to): Tuberculosis Severe scoliosis Additional Due To Contrast Injection: Allergic to iodinated contrast material Previous non-ionic contrast reaction Any conditions below regardless of eGFR Renal Disease Chronic renal dysfunction Renal Transplant (or waiting for a transplant) One kidney or other birth defect Polycystic Kidneys Renal Tumor/Renal Cancer History of liver failure/cirrhosis/liver transplant/pending liver transplant Congestive heart failure Multiple myeloma Hyperthyroidism Pheochromocytoma Sickle Cell Disease Asthma requiring daily use of inhaler Additional due to machine limitations Patient's body weight is over the limit of the scanner table (440 lbs or 200kg)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer invasive ductal carcinoma diagnosed by biopsy clinically positive node diagnosed by contrast enhance computer tomography (CECT), the number of strengthened nodes at Level I ≥ 1 with the longest diameter of the strengthened node ≥ 2cm NAC regimen followed the NCCN guideline no prior history of breast cancer or other malignancies  the cycle number of neo-adjuvant chemotherapy is equal to or less than 2
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-70.0,  Invasive Breast Cancer Invasive breast cancer diagnosed with core needle needle biopsy Staging cT1b-2N0M0 ER/PR positive cells ratio <10%, or HER2 positive (according to ASCO-CAP guidelines),and with chemotherapy indications Without chemotherapy contraindications, and planned or has started neoadjuvant chemotherapy (HER2 positive breast cancer neoadjuvant anti-HER2 treatment, or have adjuvant anti-HER2 treatment plan) With axillary sentinel lymph node biopsy indications confirmed prior to neoadjuvant therapy Voluntarily join the study and sign an informed consent form  History of malignant tumors With chemotherapy contraindications Recieved any form of surgery of primary tumor or axillary lymph nodes Refuse neoadjuvant chemotherapy Refuse assessment examinations Refuse to join the study
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Breast Neoplasms Women Age 18-65 Diagnosed with breast cancer, undergoing breast surgery Functional independence prior to the operation Ability to communicate in Hebrew  Cognitive disorders, patients unable to sign the consent form Back and spinal morbidity Fibromyalgia or chronic pain disorders Neurological disorders Renal failure with the need for dialysis Lymphedema prior to surgery History of breast surgery Shoulder surgery or shoulder injuries with limited ROM Ischemic heart disease, heart failure and radical heart insufficiency Radical mastectomy, LD and DEIP reconstruction, exchange breast prosthesis
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-100.0,  Breast Cancer Female. 2. Operated for centimeter or subcentimeter breast cancer  Previous breast cancer. 2. Metastatic breast cancer at diagnosis
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Pain, Postoperative elective primary total knee arthroplasty ASA I-III written consent  rearthroplasty ASA IV-V inadequate spoken finnish for reliable pain assessment Dementia or otherwise impaired cognition contraindication for any medication or substance used in survey protocol weight <50kg or BMI ≥35 kg/m2 preoperative SpO2 less than 93% clinical suspicion that subject can not use PCA adequately history of substance abuse or current excessive use of alcohol preoperative use of either pregabalin, gabapentin or strong opiates
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Adult female patients with breast cancer  Presence of another cancer, excluding basal cell cancers or pre-neoplastic lesions of the cervix Subject under guardianship or subject deprived of liberty Impossibility of collecting information on exposure (subjects recently arrived in France, foreign language, etc.) Male patients
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasms Gastric Cancer Colon Cancer All consecutive patients undergoing therapeutic surgery (curative or palliative) for breast, gastric, and colorectal cancer should be included Surgery is defined as a procedure requiring a skin incision performed under general or neuraxial (e.g. regional, epidural or spinal) anaesthesia Both elective and emergency procedures should be included. patients in whom the pre-operative diagnosis was thought to be benign, but was subsequently found to be cancer, e.g. bowel obstruction found to be due to cancer during surgery patients in whom the pre-operative diagnosis was thought to be cancer, but was subsequently found to be benign disease (ensure the "pathology" variable indicates not cancer; will not be included in primary analysis) Laparoscopic, laparoscopic-converted, robotic, and open cases should be included Patients aged 18 years and over should be included  Surgery may be with curative or palliative intent. patients in whom curative surgery was attempted but abandoned, e.g. open/close laparotomy  Operations where breast, gastric, or colorectal cancer is not suspected to be the primary pathology should be excluded Patients undergoing a procedure purely for diagnosis or staging should be excluded, e.g. open breast biopsy, staging laparoscopy Patients undergoing a procedure which does not require a skin incision should be excluded, e.g. colonoscopy/endoscopy alone, chemo/radiotherapy alone Patients presenting with recurrence of breast, colorectal or gastric cancer should be excluded
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 19.0-80.0,  Breast Cancer All patients enrolled before initiation of any treatment  Any other malignant or benign tumors Active inflammatory or autoimmune diseases Renal or liver diseases
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Early Breast Cancer Germline BRCA 1/2 Mutation Positive Women and men at least 18 years of age or older Histologically confirmed invasive adenocarcinoma of the breast HER2 negative breast cancer as defined by ASCO-CAP Tumor greater than or equal toT1, N0-3 No evidence of distant metastasis Adequate bone marrow, hepatic, and renal function ECOG performance status 0 or 1  Any other previous antitumor therapies for the current cancer event. Treatment for ductal carcinoma in situ (DCIS) is allowed; ie, surgery, hormonal therapy and radiation Evidence of distant metastasis apparent prior to randomization Patients with inflammatory breast carcinoma Malignancy within the last 3 years, except: Stage 1 melanoma which does not require any further treatment after adequate surgical excision; adequately treated non melanoma skin cancer; Curatively treated in situ cancer of the cervix; Stage 1, Grade 1 endometrial carcinoma; or Adequately treated contralateral breast carcinoma which has been disease free for a year; Other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for 5 years Previous or concomitant systemic anti cancer therapies used for the treatment of cancer in the last 3 years Prior treatment with a PARP inhibitor in any disease setting Concomitant use of Strong P gp inhibitors or inducers or BCRP inhibitors Patients who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol Major surgery within 14 days prior to study entry Known history of cardiac disease, for example : Myocardial infarction or symptomatic cardiac ischemia within 24 weeks before screening; Congestive heart failure New York Heart Association Class III or IV; History of clinically significant ventricular arrhythmias within one year prior to randomization; History of Mobitz II second degree or third degree heart block, uncontrolled hypertension
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.167-5.0,  Child Pneumonia Children between the ages of 2 to 59 months who is presenting with at least one of the following in the last 72 hours patient reported symptoms (cough, coryza, reported fast breathing) AND WHO (FAST (≥50 /min age if 2-12months, ≥40/min if age 1-5years) AND/OR CHEST and SIGNS (unable to drink, persistent vomiting, convulsions, lethargic or unconscious, stridor in a calm child, severe malnutrition) AND/ OR AND/OR Oxygen saturation < 96% OR CXR/CT pneumonia OR MD diagnosed pneumonia ● Patients admitted for non-respiratory symptoms may be included in the absence of  (this group will only be considered for the study if interim analysis reveals low recruitment of patients with a normal lung POCUS appearance) patients that previously underwent lung POCUS by the same lung POCUS operator during the same visit to AKUH chest tube insertion or video-assisted thoracoscopic surgery (VATS) during the current visit to AKUH (since the equipment in situ and/or dressing might bias POCUS interpretation) inability to understand informed consent